{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:23:40Z","timestamp":1772166220452,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007388","name":"Compagnia di San Paolo","doi-asserted-by":"publisher","award":["2020.AAI6.U23"],"award-info":[{"award-number":["2020.AAI6.U23"]}],"id":[{"id":"10.13039\/100007388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020324","name":"Rete Oncologica del Piemonte e della Valle d'Aosta","doi-asserted-by":"publisher","award":["26023"],"award-info":[{"award-number":["26023"]}],"id":[{"id":"10.13039\/501100020324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNC0000001"],"award-info":[{"award-number":["PNC0000001"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007364","name":"Fondazione CRT","doi-asserted-by":"publisher","award":["106562\/RF2023.1638"],"award-info":[{"award-number":["106562\/RF2023.1638"]}],"id":[{"id":"10.13039\/100007364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the era of risk-based prostate cancer (PCa) screening, overcoming the limitations of prostate-specific antigen (PSA) testing and stratifying men by individual risk is crucial. Our study aims to integrate anamnestic and lifestyle data with circulating biomarkers to minimize unnecessary second-level investigations (SLIs) for patients with suspected PCa, while improving the detection of clinically significant PCa (ISUP\u2009&gt;\u20091).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We collected plasma samples, recent clinical history, family cancer history, PSA levels, and lifestyle information from 904 men: 421 undergoing PSA testing, 421 with suspected and 62 with confirmed PCa. Univariable logistic regression was applied to identify ananmestic and lifestyle variables mostly associated with PCa. Penalized logistic regression models predictive of PCa or ISUP\u2009&gt;\u20091 PCa were built both using the 814 subjects with complete information for such variables, applying a 10-fold cross validation approach, and dividing the dataset into a training (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009445: 132 PCa, 313 non-PCa) and a test (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009369: 147 PCa, 222 non-PCa) set. The concentration of 50 sphingolipids was analysed on the latter set of 369 subjects by mass-spectrometry, and multivariable penalized regression with 10-fold cross-validation was applied to integrate anamnestic, lifestyle, sphingolipid data. ROC-AUCs on the test sets were compared with PSA ROC-AUCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Age, cardiovascular disease (CVD), number of medications, and sedentariness were significantly associated with PCa detection and their combination with PSA improved its performance (ROC-AUC from 0.85 to 0.89). In the SLI subgroup (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009437), adding age improved PSA predictive power (ROC-AUC from 0.60 to 0.70), but performance was still poor. Penalized regression with 10-fold cross-validation on the sphingolipid dataset identified hypertension, CVD, PSA, age, and five sphingolipids (HexCer-20, Cer-20, HexCer-24.1, GM3-24.1, DHCer-24) as key variables for accurate PCa classification (average ROC-AUC: 0.92). Cer-20 and CVD were consistently selected by models predicting ISUP\u2009&gt;\u20091 PCa. In the SLI subgroup, PSA, age, CVD, SM-16, HexCer-20, HexCer-24.1, DHS1P, and DHCer-24 were selected in all 10 models (average ROC-AUC: 0.83).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Circulating sphingolipids are promising biomarkers that, when combined with PSA, anamnestic, and lifestyle data, may enhance PCa screening precision and reduce the need for invasive, costly examinations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-025-06820-9","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T10:33:20Z","timestamp":1752489200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrating anamnestic and lifestyle data with sphingolipid levels for risk-based prostate cancer screening"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-2030","authenticated-orcid":false,"given":"Caterina","family":"Peraldo-Neia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4000-2954","authenticated-orcid":false,"given":"Paola","family":"Ostano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Savioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1041-7590","authenticated-orcid":false,"given":"Maurizia","family":"Mello-Grand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8810-8064","authenticated-orcid":false,"given":"Ilaria","family":"Gregnanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-5949","authenticated-orcid":false,"given":"Francesca","family":"Guana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Crivelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7359-8558","authenticated-orcid":false,"given":"Michele","family":"Dei-Cas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3186-8860","authenticated-orcid":false,"given":"Rita","family":"Paroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Sinopoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ferranti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00f2","family":"Testino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4681-888X","authenticated-orcid":false,"given":"Marco","family":"Oderda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7331-2521","authenticated-orcid":false,"given":"Andrea","family":"Zitella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Fiameni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9524-2130","authenticated-orcid":false,"given":"Amedeo","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5774-0905","authenticated-orcid":false,"given":"Alessio","family":"Naccarati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-418X","authenticated-orcid":false,"given":"Luca","family":"Clivio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9714-6596","authenticated-orcid":false,"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-3458","authenticated-orcid":false,"given":"Stefano","family":"Zaramella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9502-6400","authenticated-orcid":false,"given":"Giovanna","family":"Chiorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"6820_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euo.2023.12.005","volume":"7","author":"A Matsukawa","year":"2024","unstructured":"Matsukawa A, Yanagisawa T, Bekku K, Kardoust Parizi M, Laukhtina E, Klemm J, et al. Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: A systematic review and Meta-analysis. Eur Urol Oncol. 2024;7:697\u2013704.","journal-title":"Eur Urol Oncol"},{"key":"6820_CR2","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/annonc\/mdu525","volume":"26","author":"KS Louie","year":"2015","unstructured":"Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2015;26:848\u201364.","journal-title":"Ann Oncol"},{"key":"6820_CR3","doi-asserted-by":"publisher","first-page":"769158","DOI":"10.3389\/fonc.2021.769158","volume":"11","author":"M Mello-Grand","year":"2021","unstructured":"Mello-Grand M, Bruno A, Sacchetto L, Cristoni S, Gregnanin I, Dematteis A, et al. Two novel Ceramide-Like molecules and miR-5100 levels as biomarkers improve prediction of prostate Cancer in Gray-Zone PSA. Front Oncol. 2021;11:769158.","journal-title":"Front Oncol"},{"key":"6820_CR4","doi-asserted-by":"publisher","first-page":"11178","DOI":"10.3390\/ijms231911178","volume":"23","author":"P Pal","year":"2022","unstructured":"Pal P, Atilla-Gokcumen GE, Frasor J. Emerging roles of ceramides in breast Cancer biology and therapy. IJMS. 2022;23:11178.","journal-title":"IJMS"},{"key":"6820_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41580-018-0046-6","volume":"19","author":"YA Hannun","year":"2018","unstructured":"Hannun YA, Obeid LM. Author correction: sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19:673.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6820_CR6","doi-asserted-by":"publisher","first-page":"925807","DOI":"10.3389\/fonc.2022.925807","volume":"12","author":"DN Petrusca","year":"2022","unstructured":"Petrusca DN, Lee KP, Galson DL. Role of sphingolipids in multiple myeloma progression, drug resistance, and their potential as therapeutic targets. Front Oncol. 2022;12:925807.","journal-title":"Front Oncol"},{"key":"6820_CR7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41391-021-00338-z","volume":"24","author":"H-M Lin","year":"2021","unstructured":"Lin H-M, Huynh K, Kohli M, Tan W, Azad AA, Yeung N, et al. Aberrations in Circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:860\u201370.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6820_CR8","doi-asserted-by":"publisher","first-page":"17791","DOI":"10.1038\/s41598-023-44157-9","volume":"13","author":"C Cattrini","year":"2023","unstructured":"Cattrini C, Manfredi M, Barboro P, Ghirimoldi M, Mennitto A, Martini V, et al. Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients. Sci Rep. 2023;13:17791.","journal-title":"Sci Rep"},{"key":"6820_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41391-023-00666-2","volume":"27","author":"T Scheinberg","year":"2024","unstructured":"Scheinberg T, Lin H-M, Fitzpatrick M, Azad AA, Bonnitcha P, Davies A, et al. PCPro: a clinically accessible, Circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2024;27:136\u201343.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6820_CR10","doi-asserted-by":"publisher","first-page":"22069","DOI":"10.1038\/s41598-024-73074-8","volume":"14","author":"MC Finnerty","year":"2024","unstructured":"Finnerty MC, Leach FE, Zakharia Y, Nepple KG, Bartlett MG, Henry MD, et al. Identification of blood lipid markers of docetaxel treatment in prostate cancer patients. Sci Rep. 2024;14:22069.","journal-title":"Sci Rep"},{"key":"6820_CR11","doi-asserted-by":"publisher","first-page":"103625","DOI":"10.1016\/j.ebiom.2021.103625","volume":"72","author":"H-M Lin","year":"2021","unstructured":"Lin H-M, Mak B, Yeung N, Huynh K, Meikle TG, Mellett NA, et al. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. eBioMedicine. 2021;72:103625.","journal-title":"eBioMedicine"},{"key":"6820_CR12","doi-asserted-by":"crossref","unstructured":"Lee C, Chen Y, Hernandez E, Pong R, Ma S, Hofstad M, The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC., Clinical et al. & Translational Med [Internet]. 2022 [cited 2023 Feb 28];12. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ctm2.695","DOI":"10.1002\/ctm2.695"},{"key":"6820_CR13","doi-asserted-by":"publisher","first-page":"eadh1922","DOI":"10.1126\/scisignal.adh1922","volume":"17","author":"CF Ribeiro","year":"2024","unstructured":"Ribeiro CF, Rodrigues S, Bastos DC, Fanelli GN, Pakula H, Foiani M, et al. Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP Inhibition. Sci Signal. 2024;17:eadh1922.","journal-title":"Sci Signal"},{"key":"6820_CR14","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.3390\/cancers13133140","volume":"13","author":"X Lin","year":"2021","unstructured":"Lin X, L\u00e9cuyer L, Liu X, Triba MN, Deschasaux-Tanguy M, Demidem A, et al. Plasma metabolomics for discovery of early metabolic markers of prostate Cancer based on Ultra-High-Performance liquid Chromatography-High resolution mass spectrometry. Cancers (Basel). 2021;13:3140.","journal-title":"Cancers (Basel)"},{"key":"6820_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12916-022-02553-4","volume":"20","author":"M Breeur","year":"2022","unstructured":"Breeur M, Ferrari P, Dossus L, Jenab M, Johansson M, Rinaldi S, et al. Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European prospective investigation into Cancer and nutrition. BMC Med. 2022;20:351.","journal-title":"BMC Med"},{"key":"6820_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12916-017-0885-6","volume":"15","author":"JA Schmidt","year":"2017","unstructured":"Schmidt JA, Fensom GK, Rinaldi S, Scalbert A, Appleby PN, Achaintre D, et al. Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European prospective investigation into Cancer and nutrition. BMC Med. 2017;15:122.","journal-title":"BMC Med"},{"key":"6820_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ijc.32314","volume":"146","author":"JA Schmidt","year":"2020","unstructured":"Schmidt JA, Fensom GK, Rinaldi S, Scalbert A, Appleby PN, Achaintre D, et al. Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case\u2013control sets from EPIC. Int J Cancer. 2020;146:720\u201330.","journal-title":"Int J Cancer"},{"key":"6820_CR18","unstructured":"World Cancer Research Fund\/American Institute for Cancer Research. Continuous update project expert report 2018. Recommendations and public health and policy implications. Available at dietandcancerreport.org."},{"key":"6820_CR19","doi-asserted-by":"publisher","first-page":"861526","DOI":"10.3389\/fnut.2022.861526","volume":"9","author":"L Rossi","year":"2022","unstructured":"Rossi L, Berni Canani S, Censi L, Gennaro L, Leclercq C, Scognamiglio U, et al. The 2018 revision of Italian dietary guidelines: development process, novelties, main recommendations, and policy implications. Front Nutr. 2022;9:861526.","journal-title":"Front Nutr"},{"key":"6820_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.euros.2024.09.003","volume":"70","author":"A Chandran","year":"2024","unstructured":"Chandran A, Van Harten M, Singh D, Vilaseca J, Patasius A, Tupikowski K, et al. Risk-stratified approach to implementing Population-based prostate Cancer screening in five pilot sites in the European union: A protocol for the PRAISE-U project. Eur Urol Open Sci. 2024;70:8\u201317.","journal-title":"Eur Urol Open Sci"},{"key":"6820_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/jcm13020487","volume":"13","author":"S Osama","year":"2024","unstructured":"Osama S, Serboiu C, Taciuc I-A, Angelescu E, Petcu C, Priporeanu TA, et al. Current approach to complications and difficulties during transrectal Ultrasound-Guided prostate biopsies. J Clin Med. 2024;13:487.","journal-title":"J Clin Med"},{"key":"6820_CR22","doi-asserted-by":"publisher","first-page":"175628722211039","DOI":"10.1177\/17562872221103988","volume":"14","author":"MW Farha","year":"2022","unstructured":"Farha MW, Salami SS. Biomarkers for prostate cancer detection and risk stratification. Ther Adv Urol. 2022;14:17562872221103988.","journal-title":"Ther Adv Urol"},{"key":"6820_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/ije\/dyu090","volume":"43","author":"OA Andreassen","year":"2014","unstructured":"Andreassen OA, Zuber V, Thompson WK, Schork AJ, Bettella F, Consortium PRACTICAL, et al. Shared common variants in prostate cancer and blood lipids. Int J Epidemiol. 2014;43:1205\u201314.","journal-title":"Int J Epidemiol"},{"key":"6820_CR24","doi-asserted-by":"publisher","first-page":"28465","DOI":"10.1038\/s41598-024-78787-4","volume":"14","author":"T Bai","year":"2024","unstructured":"Bai T, Wu C. Association of cardiovascular disease on cancer: observational and Mendelian randomization analyses. Sci Rep. 2024;14:28465.","journal-title":"Sci Rep"},{"key":"6820_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13148-024-01756-1","volume":"16","author":"M Nagata","year":"2024","unstructured":"Nagata M, Komaki S, Nishida Y, Ohmomo H, Hara M, Tanaka K, et al. Influence of physical activity on the epigenetic clock: evidence from a Japanese cross-sectional study. Clin Epigenetics. 2024;16:142.","journal-title":"Clin Epigenetics"},{"key":"6820_CR26","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.euf.2020.05.002","volume":"7","author":"A Mortezavi","year":"2021","unstructured":"Mortezavi A, Palsdottir T, Eklund M, Chellappa V, Murugan SK, Saba K, et al. Head-to-head comparison of conventional, and Image- and Biomarker-based prostate Cancer risk calculators. Eur Urol Focus. 2021;7:546\u201353.","journal-title":"Eur Urol Focus"},{"key":"6820_CR27","first-page":"CD012663","volume":"4","author":"F-JH Drost","year":"2019","unstructured":"Drost F-JH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4:CD012663.","journal-title":"Cochrane Database Syst Rev"},{"key":"6820_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.euo.2018.02.010","volume":"1","author":"CK Mannaerts","year":"2018","unstructured":"Mannaerts CK, Gayet M, Verbeek JF, Engelbrecht MRW, Savci-Heijink CD, Jager GJ, et al. Prostate Cancer risk assessment in biopsy-na\u00efve patients: the Rotterdam prostate Cancer risk calculator in multiparametric magnetic resonance Imaging-Transrectal ultrasound (TRUS) fusion biopsy and systematic TRUS biopsy. Eur Urol Oncol. 2018;1:109\u201317.","journal-title":"Eur Urol Oncol"},{"key":"6820_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.eururo.2017.02.026","volume":"72","author":"PC Moldovan","year":"2017","unstructured":"Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, et al. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate Cancer at biopsy?? A systematic review and Meta-analysis from the European association of urology prostate Cancer guidelines panel. Eur Urol. 2017;72:250\u201366.","journal-title":"Eur Urol"},{"key":"6820_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40364-024-00678-7","volume":"12","author":"JR Gregg","year":"2024","unstructured":"Gregg JR, Newcomb L, Wu R, Dennison J, Davis JW, Pettaway C, et al. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomark Res. 2024;12:134.","journal-title":"Biomark Res"},{"key":"6820_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fcell.2019.00210","volume":"7","author":"D Wigger","year":"2019","unstructured":"Wigger D, Gulbins E, Kleuser B, Schumacher F. Monitoring the sphingolipid de Novo synthesis by Stable-Isotope labeling and liquid Chromatography-Mass spectrometry. Front Cell Dev Biol. 2019;7:210.","journal-title":"Front Cell Dev Biol"},{"key":"6820_CR32","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/ijc.30903","volume":"141","author":"H Lin","year":"2017","unstructured":"Lin H, Mahon KL, Weir JM, Mundra PA, Spielman C, Briscoe K, et al. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. Intl J Cancer. 2017;141:2112\u201320.","journal-title":"Intl J Cancer"},{"key":"6820_CR33","doi-asserted-by":"publisher","first-page":"745092","DOI":"10.3389\/fonc.2021.745092","volume":"11","author":"O Companioni","year":"2021","unstructured":"Companioni O, Mir C, Garcia-Mayea Y, LLeonart ME. Targeting sphingolipids for Cancer therapy. Front Oncol. 2021;11:745092.","journal-title":"Front Oncol"},{"key":"6820_CR34","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.3390\/ijms22105076","volume":"22","author":"N Sasaki","year":"2021","unstructured":"Sasaki N, Toyoda M, Ishiwata T. Gangliosides as signaling regulators in Cancer. IJMS. 2021;22:5076.","journal-title":"IJMS"},{"key":"6820_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/glycob\/cwj105","volume":"16","author":"H-J Choi","year":"2006","unstructured":"Choi H-J, Chung T-W, Kang S-K, Lee Y-C, Ko J-H, Kim J-G, et al. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression\u2014transcriptional induction of p21WAF1 and p27kip1 by Inhibition of PI-3K\/AKT pathway. Glycobiology. 2006;16:573\u201383.","journal-title":"Glycobiology"},{"key":"6820_CR36","doi-asserted-by":"publisher","first-page":"e74768","DOI":"10.1371\/journal.pone.0074768","volume":"8","author":"MW Holliday Jr","year":"2013","unstructured":"Holliday MW Jr., Cox SB, Kang MH, Maurer BJ. LJ Siskind editor 2013 C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-Cell acute lymphoblastic leukemia cell lines. PLoS ONE 8 e74768.","journal-title":"PLoS ONE"},{"key":"6820_CR37","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00018-018-2984-8","volume":"76","author":"RR Magaye","year":"2019","unstructured":"Magaye RR, Savira F, Hua Y, Kelly DJ, Reid C, Flynn B, et al. The role of dihydrosphingolipids in disease. Cell Mol Life Sci. 2019;76:1107\u201334.","journal-title":"Cell Mol Life Sci"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06820-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:46:53Z","timestamp":1757234813000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06820-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6820"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06820-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.03.07.25323552","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The observational clinical protocol called DP3 coordinated by FEET was approved by the Novara ethical committee (AOU Maggiore della Carit\u00e0) in September 2020 (Prot. N\u00b0 968\/CE 07\/09\/2020, integration Prot. N\u00b0263\/CE, 10\/03\/2021), in accordance with the Declaration of Helsinki Ethical Principles for Medical Research involving Human Participants. The MH ethical committee (AOU Citt\u00e0 della Salute e della Scienza) in Turin approved the DP3 study in January 2022 (Prot. N\u00b0 521\/2021, 10\/01\/2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"790"}}